Intellectual Property


Q-Sera’s technology is based upon research emanating from the University of Queensland and is patent protected.

Family 1 Priority Date Sept 2010

'Serum Preparation'
PCTAU2011/001221

This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.

August 2019: Patent granted or approved in US, EU, Japan, China, Canada, Mexico, Russia, South Africa and Australia.
Patent pending in South Korea, India, Israel and Brazil.

Family 2 Priority Date Oct 2014

'Improved Clotting Composition'
PCTAU2015/000629

Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.

Examination ongoing.